High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.
SRTD Biotech
Seed Round in 2024
SRTD Biotech is a biotechnology company specializing in RNA-based therapies. It develops a pro-drug platform targeting various diseases, including cancer, viral infections, and genetic disorders. The company's approach involves selectively delivering RNA to specific organs using techniques such as RNAi interference, mRNA therapy, and fusogenic liposomes, enabling the treatment of previously untreatable conditions.
Aignostics
Series B in 2024
Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.
Kranus Health
Series A in 2023
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Hema.to
Seed Round in 2023
Hema.to is a developer of clinical support software that specializes in automated, AI-powered detection suggestions for blood cancer, utilizing flow cytometry data. The company's platform offers comprehensive decision support, taking users from raw flow files to complete diagnostic reports. By focusing on the needs of hematology laboratories, Hema.to aims to enhance operational efficiency while ensuring high-quality results. Its tools are specifically designed to meet the unique requirements of clinical flow, empowering labs to provide better patient care through advanced technology.
hbox
Seed Round in 2023
HBOX Therapies is a developer of technology that facilitates the lung-protective treatment of respiratory patients. They produce miniaturized hyperoxygenation therapies. The technology's application is miniature respiratory assistance for patients suffering from lung failure.
PraxisEins.
Pre Seed Round in 2023
PraxisEins is a healthcare startup focused on creating software solutions for outpatient care. The company aims to enhance patient care by digitizing processes for physicians, thereby alleviating administrative burdens. Their platform enables healthcare providers to conduct same-day consultations, addressing the need for more efficient outpatient services. By leveraging modern technology, PraxisEins seeks to streamline operations for doctors of all ages, ultimately improving the overall healthcare experience for both practitioners and patients.
Aignostics
Series A in 2022
Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.
Kranus Health
Series A in 2022
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Emergence Therapeutics
Series A in 2021
Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.
Cardior Pharmaceuticals
Series B in 2021
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.
Kranus Health
Seed Round in 2021
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
heartbeat medical
Series A in 2020
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Aignostics
Seed Round in 2020
Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics in pathology, employing its patented technology to create explainable AI systems that address the limitations of traditional AI models. By generating precise heatmaps and image overlays, Aignostics' platform enables pathologists to quickly verify AI-generated diagnostic results. This capability is essential for ensuring accuracy in diagnoses, particularly for complex diseases such as cancer. The company's innovative approach supports the discovery and validation of biomarkers, facilitating improved diagnosis and treatment strategies in precision medicine.
heartbeat medical
Venture Round in 2017
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Cardior Pharmaceuticals
Series A in 2017
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.
KSK Diagnostics
Series A in 2017
KSK Diagnostics GmbH, established in 2014 and based in Hamburg, Germany, specializes in the development of molecular point-of-care diagnostic assays aimed at diagnosing infectious diseases and cancer. The company utilizes isothermal amplification technology to create rapid tests that enable healthcare professionals to make timely diagnoses, often within 30 minutes, thereby facilitating prompt treatment decisions. In addition to its diagnostic assays, KSK Diagnostics offers customizable services, including the development of nucleic acid-based tests using real-time PCR or RT-PCR, as well as verification and validation studies and product enhancement services for other organizations in the healthcare sector. As a pioneer in this field, KSK Diagnostics is dedicated to improving patient-oriented diagnostics through innovative technologies.
Cunesoft
Series A in 2016
Cunesoft GmbH is a provider of cloud-based regulatory compliance software solutions tailored for the life sciences industry. Established in 2013 and headquartered in Munich, Germany, with offices in Princeton, New Jersey, and Bengaluru, India, Cunesoft offers a range of Software as a Service (SaaS) products. These include cune-IDMP, a master data management tool for accessing external regulatory databases; cune-eCTD, which facilitates electronic submission creation; and cune-Track, a workflow management system for regulatory tasks. Additionally, the company provides cune-RDMS for document navigation and tagging, cune-SOP for standard operating procedures, and cune-Portal for sharing regulatory documents. Cunesoft also offers outsourcing services for regulatory procedures and documentation. The company’s software is designed for quick deployment and is utilized by both small and medium-sized enterprises and larger pharmaceutical divisions globally, emphasizing reliability, security, and compliance. Cunesoft operates as a subsidiary of Phlexglobal Ltd. since January 2020.
heartbeat medical
Venture Round in 2016
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Cunesoft
Seed Round in 2014
Cunesoft GmbH is a provider of cloud-based regulatory compliance software solutions tailored for the life sciences industry. Established in 2013 and headquartered in Munich, Germany, with offices in Princeton, New Jersey, and Bengaluru, India, Cunesoft offers a range of Software as a Service (SaaS) products. These include cune-IDMP, a master data management tool for accessing external regulatory databases; cune-eCTD, which facilitates electronic submission creation; and cune-Track, a workflow management system for regulatory tasks. Additionally, the company provides cune-RDMS for document navigation and tagging, cune-SOP for standard operating procedures, and cune-Portal for sharing regulatory documents. Cunesoft also offers outsourcing services for regulatory procedures and documentation. The company’s software is designed for quick deployment and is utilized by both small and medium-sized enterprises and larger pharmaceutical divisions globally, emphasizing reliability, security, and compliance. Cunesoft operates as a subsidiary of Phlexglobal Ltd. since January 2020.
PERORA
Seed Round in 2013
PERORA GmbH is a biotechnology company based in Heidelberg, Germany, established in 2013. The company develops innovative solutions for weight management and obesity treatment, notably through a polymer-based fat-binding medical device. Additionally, PERORA produces and markets REDIA, a nutritional supplement recognized for its health benefits, specifically in lowering postprandial blood sugar levels. This product has received patents in the European Union, the United States, and other countries, and has been clinically validated for use in patients with type 2 diabetes. REDIA is available for purchase in Germany through its website and various online pharmacies. PERORA aims to expand its offerings by establishing a subscription model for the self-management of chronic, age-related metabolic health in Europe and seeks to license its products for international markets.
Humedics
Series A in 2011
Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in the development of a breath analysis device designed to assess liver function in patients suffering from liver failure. The company's key product, the LiMAx test, is a diagnostic system that includes a medical device, breath masks, and a diagnostic drug, enabling clinicians to quantitatively evaluate individual liver function. This technology supports various applications, such as assessing liver function before and after transplantation, planning liver surgeries, and evaluating conditions like liver cirrhosis. By providing rapid and precise measurements at the bedside, LiMAx facilitates informed decision-making for tailored medical treatments, thereby enhancing patient outcomes. The company has successfully used its technology with thousands of patients and is focused on expanding its global operations.
Humedics
Seed Round in 2010
Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in the development of a breath analysis device designed to assess liver function in patients suffering from liver failure. The company's key product, the LiMAx test, is a diagnostic system that includes a medical device, breath masks, and a diagnostic drug, enabling clinicians to quantitatively evaluate individual liver function. This technology supports various applications, such as assessing liver function before and after transplantation, planning liver surgeries, and evaluating conditions like liver cirrhosis. By providing rapid and precise measurements at the bedside, LiMAx facilitates informed decision-making for tailored medical treatments, thereby enhancing patient outcomes. The company has successfully used its technology with thousands of patients and is focused on expanding its global operations.
Public Health Solutions
Venture Round in 2008
Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.
Public Health Solutions
Series A in 2006
Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.